• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Silk Road Medical Inc.

    7/10/24 1:45:37 PM ET
    $SILK
    Medical/Dental Instruments
    Health Care
    Get the next $SILK alert in real time by email
    SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 4 )*

                

    Silk Road Medical, Inc.


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    82710M100


    (CUSIP Number)

    June 28, 2024


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. 82710M100

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    Capital World Investors
    95-1411037
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 969,500
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER 969,500
    8. SHARED DISPOSITIVE POWER 0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    969,500 Beneficial ownership disclaimed pursuant to Rule 13d-4
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.5%
    12. TYPE OF REPORTING PERSON

    IA

    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    


    Item 1.
    (a) Name of Issuer
    Silk Road Medical, Inc.
    (b) Address of Issuer's Principal Executive Offices
    1213 INNSBRUCK DR., SUNNYVALE, CA 94089
    Item 2.
    (a) Name of Person Filing
    Capital World Investors
    (b) Address of Principal Business Office or, if None, Residence
    333 SOUTH HOPE STREET, 55TH FLOOR, LOS ANGELES, CALIFORNIA 90071
    (c) Citizenship
    N/A
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    82710M100
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    969,500 **
    (b) Percent of Class:
    2.5%
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 969,500
    (ii) shared power to vote or to direct the vote 0
    (iii) sole power to dispose or to direct the disposition of 969,500
    (iv) shared power to dispose or to direct the disposition of 0
    **Capital World Investors ("CWI") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CWI's divisions of each of the investment management entities collectively provide investment management services under the name "Capital World Investors." CWI is deemed to be the beneficial owner of 969,500 shares or 2.5% of the 39,443,868 shares believed to be outstanding.
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ X ]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    Not Applicable
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Not Applicable
    Item 8. Identification and Classification of Members of the Group.
    Not Applicable. This schedule is not being filed pursuant to Rule 13d-1(b)(1)(ii)(J) or Rule 13d-1(d).
    Item 9. Notice of Dissolution of Group.

    Not Applicable
    Item 10. Certification.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Capital World Investors
    By: /s/ Erik A. Vayntrub
    Date: July 08, 2024
    Name: Erik A. Vayntrub
    Title: Senior Vice President and Senior Counsel, Fund Business Management Group, Capital Research and Management Company

    Get the next $SILK alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SILK

    DatePrice TargetRatingAnalyst
    7/11/2024Buy → Sell
    Argus
    3/7/2024$24.00Hold → Buy
    Argus
    1/19/2024$9.00 → $20.00Hold → Buy
    Stifel
    1/3/2024$20.00Buy
    Lake Street
    10/24/2023Underperform → Peer Perform
    Wolfe Research
    10/11/2023$54.00 → $14.00Buy → Neutral
    B. Riley Securities
    10/11/2023Buy → Neutral
    CL King
    10/11/2023$45.00 → $12.00Buy → Hold
    Stifel
    More analyst ratings

    $SILK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Boston Scientific Announces Results for Third Quarter 2024

      MARLBOROUGH, Mass., Oct. 23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $469 million or $0.32 per share (EPS), compared to $505 million or $0.34 per share a year ago, and achieved adjusted3 EPS of $0.63 for the period, compared to $0.50 a year ago.

      10/23/24 6:30:00 AM ET
      $BSX
      $SILK
      Medical/Dental Instruments
      Health Care
    • Boston Scientific Closes Acquisition of Silk Road Medical, Inc.

      MARLBOROUGH, Mass., Sept. 17, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Silk Road Medical, Inc. (NASDAQ:SILK), a medical device company that pioneered a new approach for stroke prevention and the treatment of carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR). "Completing this acquisition enables Boston Scientific to strengthen our vascular technology solutions by bringing the innovative TCAR platform to a greater number of physicians and their pa

      9/17/24 8:31:00 AM ET
      $BSX
      $SILK
      Medical/Dental Instruments
      Health Care
    • SILK Alert: Monsey Firm of Wohl & Fruchter Renews Investigation of the Proposed Sale of Silk Road Medical to Boston Scientific

      MONSEY, N.Y., Aug. 19, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP has renewed its investigation into the fairness of the proposed sale of Silk Road Medical, Inc. (NASDAQ:SILK) ("SILK") to Boston Scientific Corporation for $27.50 per share in cash. On July 29, 2024, SILK filed a definitive proxy concerning the proposed sale with the SEC. Based on our review of the proxy, we have renewed our investigation into whether there are any undisclosed potential conflicts of interest. If you remain a SILK shareholder and question the fairness of the price or have any other concerns, you may contact our firm at the following link to discuss your legal rights at no charge: https:/

      8/19/24 9:31:00 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    SEC Filings

    See more
    • SEC Form 15-12G filed by Silk Road Medical Inc.

      15-12G - Silk Road Medical Inc (0001397702) (Filer)

      9/27/24 4:00:39 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Silk Road Medical Inc.

      EFFECT - Silk Road Medical Inc (0001397702) (Filer)

      9/24/24 12:15:03 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • SEC Form 25-NSE filed by Silk Road Medical Inc.

      25-NSE - Silk Road Medical Inc (0001397702) (Subject)

      9/17/24 9:33:30 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ballinger Kevin J. bought $198,783 worth of shares (11,700 units at $16.99), increasing direct ownership by 192% to 17,807 units (SEC Form 4)

      4 - Silk Road Medical Inc (0001397702) (Issuer)

      3/7/24 6:01:30 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Silk Road Medical downgraded by Argus

      Argus downgraded Silk Road Medical from Buy to Sell

      7/11/24 7:47:06 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Silk Road Medical upgraded by Argus with a new price target

      Argus upgraded Silk Road Medical from Hold to Buy and set a new price target of $24.00

      3/7/24 7:36:37 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Silk Road Medical upgraded by Stifel with a new price target

      Stifel upgraded Silk Road Medical from Hold to Buy and set a new price target of $20.00 from $9.00 previously

      1/19/24 8:14:13 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Zurbay Donald returned 12,610 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Silk Road Medical Inc (0001397702) (Issuer)

      9/18/24 9:12:36 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Director Weatherman Elizabeth H returned 155,004 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Silk Road Medical Inc (0001397702) (Issuer)

      9/18/24 9:08:24 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Director Lasersohn Jack W returned 16,735 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Silk Road Medical Inc (0001397702) (Issuer)

      9/18/24 9:01:12 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    Leadership Updates

    Live Leadership Updates

    See more
    • Silk Road Medical Names Chas McKhann Chief Executive Officer

      SUNNYVALE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (NASDAQ:SILK) ("Silk Road" or the "Company"), a company focused on reducing the risk of stroke and its devastating impact, today announced that Chas McKhann has been appointed Chief Executive Officer (CEO), effective immediately. Mr. McKhann is an accomplished leader with more than 25 years of experience in the medical device industry, including C-suite positions at seven public and private companies. Most recently, Mr. McKhann served as President and CEO of Apollo Endosurgery (acquired by Boston Scientific in April 2023), where he created and led a transformational growth strategy for the company's minimal

      11/2/23 8:00:00 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Silk Road Medical Announces Retirement of CEO Erica Rogers

      Working with Leading Executive Search Firm to Identify Successor SUNNYVALE, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (NASDAQ:SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that CEO Erica Rogers plans to retire from the Company following the completion of a succession process. The Company is working with Spencer Stuart, a leading executive search firm. To ensure a smooth transition, Ms. Rogers will remain as President and CEO of the Company until her successor is appointed. "I'd like to thank Erica for her tremendous contributions to Silk Road over the last 11 years. Erica has been integral in leading and expand

      10/10/23 4:20:00 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Silk Road Medical Names Dr. Tanisha Carino to Board of Directors

      SUNNYVALE, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (NASDAQ:SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that it has appointed Dr. Tanisha Carino to its Board of Directors. Tanisha Carino, Ph.D., is a health policy expert bringing over 20 years of experience driving growth and impact across multiple healthcare leadership positions in the government, private, and non-profit sectors. She most recently served as Executive Vice President, Chief Corporate Affairs Officer of Alexion, a Fortune 500 biotechnology company focused on rare disease, which was recently acquired by AstraZeneca.   Prior to Alexion, she serv

      7/26/21 4:05:00 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    Financials

    Live finance-specific insights

    See more
    • Boston Scientific Announces Results for Third Quarter 2024

      MARLBOROUGH, Mass., Oct. 23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $469 million or $0.32 per share (EPS), compared to $505 million or $0.34 per share a year ago, and achieved adjusted3 EPS of $0.63 for the period, compared to $0.50 a year ago.

      10/23/24 6:30:00 AM ET
      $BSX
      $SILK
      Medical/Dental Instruments
      Health Care
    • Boston Scientific Announces Results for Second Quarter 2024

      MARLBOROUGH, Mass., July 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent on a reported basis, 16.1 percent on an operational1 basis and 14.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $324 million or $0.22 per share (EPS), compared to $261 million or $0.18 per share a year ago, and achieved adjusted3 EPS of $0.62 for the period, compared to $0.53 a year ago.

      7/24/24 6:30:00 AM ET
      $BSX
      $SILK
      Medical/Dental Instruments
      Health Care
    • Silk Road Medical Reports First Quarter 2024 Financial Results

      SUNNYVALE, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (NASDAQ:SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended March 31, 2024. "Our team delivered a strong start to 2024 as we deepened relationships with the physicians we serve and continued broadening our patient impact," said Chas McKhann, CEO of Silk Road Medical. "In the first quarter, we made meaningful commercial progress while also taking steps toward sustainable profitability. We enter the second quarter feeling energized by TCAR's outstanding value proposition for physicians and patients and in our opportun

      4/30/24 4:05:00 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Silk Road Medical Inc.

      SC 13D/A - Silk Road Medical Inc (0001397702) (Subject)

      9/19/24 8:16:37 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by Silk Road Medical Inc.

      SC 13D - Silk Road Medical Inc (0001397702) (Subject)

      8/12/24 4:21:48 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Silk Road Medical Inc.

      SC 13G/A - Silk Road Medical Inc (0001397702) (Subject)

      7/10/24 1:45:37 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care